

0000

RESEARCH DIVISION AT AHVI

SUMMER NEWSLETTER 2025



We're thrilled to announce the first enrollment in the GREAT Trial—our newest venture exploring a novel atherectomy device for treating peripheral arterial disease (PAD).

This innovative technology is designed to enhance plaque removal efficiency and improve outcomes for patients suffering from symptoms related to the condition.


Fun Fact: The device is named "Golazo", Spanish for a spectacular goal—perfectly suited to our team's drive and precision!

Join Us on This Journey

We're proud to contribute to this next chapter in cardiovascular science and are grateful for our incredible patients, referring physicians, research coordinators, and sponsors who make this possible.


If you're interested in referring patients, learning more, or collaborating on future research, reach out to our Research Division today.

PARAMOUNT Study: Predicting Risk Like Never Before



In collaboration with Cleerly and powered by CCT, and advanced AI analysis, the PARAMOUNT study is transforming how we understand and quantify coronary artery disease in the setting of patients presenting with chest pain. With precise plaque characterization and risk modeling, we're redefining the future of preventative cardiology.

TRANSFORM Trial: Precision Imaging for the Next Generation



The TRANSFORM trial further builds on the power of Cleerly's artificial intelligence to evaluate coronary artery plaque, vessel remodeling, and subclinical disease in high-risk patients. Early insights are already shaping our approach to diagnosis and therapy optimization.

At the Advanced Heart and Vascular Institute of Hunterdon, innovation isn't just a buzzword—it's our mission. Our research division continues to gain momentum with three cutting-edge clinical trials that place us at the forefront of cardiovascular discovery.

Why it matters?

These studies are more than protocols—they're part of a larger mission to elevate cardiovascular care, refine diagnostics, and bring safer, more effective treatment options to our patients and communities.



om (

